Back to discover
Disease

Hypotension

Late-stage therapeutic developmentEmerging research
2
Publications
24
Clinical trials
2021
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Clinical Milestones10View all 10
+2 more in the activity timeline below
Activity timeline10

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Dopamineapproved

Approval — Treatment of hypotension in haemodynamically unstable neonates, infants and children <… (2024)

Clinical trials

17 sponsors · 1 new · 3 completed in the last 12 months (net +1)

The current development programme across all trial phases.

Clinical programme
24
All trials
6
Active
18
Late-stage
6
Completed
Late-stage studies
Recruiting
Recently completed

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2024emaApprovalDopamine· Treatment of hypotension in haemodynamically unstable neonates, infants and children < 18 years source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20192021
Leading journals2
  • JAMA1
  • The New England journal of medicine1
Leading researchers8
  • Albert M1
  • Bandeen-Roche K1
  • Bhatt DL1
  • Cannon CP1
  • Coresh J1
  • Gottesman RF1
  • Gross AL1
  • Knopman DS1
Affiliations (unnormalised)6
  • From Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School1
  • George Washington University Milken Institute School of Public Health1
  • Johns Hopkins Bloomberg School of Public Health1
  • Johns Hopkins Center on Aging and Health1
  • Johns Hopkins University School of Medicine1
  • Mayo Clinic1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.

Identifiers
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.